Progress of the aryl hydrocarbon receptor in inflammatory skin diseases

doi:10.11958/20240117

Abstract

Abstract:

The aryl hydrocarbon receptor (AhR), also known as dioxin receptor, is a ligand-dependent transcription factor. Because of its important role in occurrence and development of cancer, it has been widely studied. AhR is now considered to be an important regulator of host-environment interactions in immune and inflammatory responses and is involved in pathogenesis of many skin diseases. Because AhR is highly expressed in all types of skin cells and regulates many genes that are critical to skin function, it has the potential to be a new target for the treatment of inflammatory skin diseases. This paper presents and analyzes research findings on the relationship between AhR and inflammatory skin diseases to help accelerate the development of new drugs.

Key words: receptors, aryl hydrocarbon, inflammation, skin diseases

CLC Number:

R751

Figures/Tables 1

References 46

[1]	OPITZ C A, HOLFELDER P, PRENTZELL M T, et al. The complex biology of aryl hydrocarbon receptor activation in cancer and beyond[J]. Biochem Pharmacol, 2023,216:115798. doi:10.1016/j.bcp.2023.115798.
[2]	GUILLON C, MEZIANI M, ABDELLI S, et al. The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants[J]. Eur J Dermatol, 2022, 32(3):305-311. doi:10.1684/ejd.2022.4262.
[3]	ACCIOLI C, DA S M, SANTOS B, et al. Aryl hydrocarbon receptor as a therapeutical target of environmentally induced skin conditions[J]. Mol Pharmacol, 2023, 103(5):255-265. doi:10.1124/molpharm.122.000627.
[4]	BUNGSU I, KIFLI N, AHMAD S R, et al. Herbal plants:the role of AhR in mediating immunomodulation[J]. Front Immunol, 2021,12:697663. doi:10.3389/fimmu.2021.697663.
[5]	KEAM S J. Tapinarof cream 1%:first approval[J] Drugs, 2022, 82(11):1221-1228. doi:10.1007/s40265-022-01748-6.
[6]	KIM H B, UM J Y, CHUNG B Y, et al. Aryl hydrocarbon receptors:evidence of therapeutic targets in chronic inflammatory skin diseases[J]. Biomedicines, 2022, 10(5):1087. doi:10.3390/biomedicines10051087.
[7]	KOU Z, TRAN F, DAI W. Heavy metals,oxidative stress,and the role of AhR signaling[J]. Toxicol Appl Pharmacol, 2024,482:116769. doi:10.1016/j.taap.2023.116769.
[8]	SAFE S, JIN U H, PARK H, et al. Aryl hydrocarbon receptor (AHR) ligands as selective AHR modulators (SAhRMs)[J]. Int J Mol Sci, 2020, 21(18):6654. doi:10.3390/ijms21186654.
[9]	GRANADOS J C, FALAH K, KOO I, et al. AHR is a master regulator of diverse pathways in endogenous metabolism[J]. Sci Rep, 2022, 12(1):16625. doi:10.1038/s41598-022-20572-2.
[10]	REJANO-GORDILLO C M, MARIN-DIAZ B, ORDIALES-TALAVERO A, et al. From nucleus to organs:insights of aryl hydrocarbon receptor molecular mechanisms[J]. Int J Mol Sci, 2022, 23(23):14919. doi:10.3390/ijms232314919.
[11]	NAPOLITANO M, FABBROCINI G, MARTORA F, et al. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases[J]. Cells, 2021, 10(12):3559. doi:10.3390/cells10123559.
[12]	LIU H M, CHENG M Y, XUN M H, et al. Possible mechanisms of oxidative stress-induced skin cellular senescence,inflammation,and cancer and the therapeutic potential of plant polyphenols[J]. Int J Mol Sci, 2023, 24(4):3755. doi:10.3390/ijms24043755.
[13]	SANTIBANEZ-ANDRADE M, QUEZADA-MALDONADO E M, RIVERA-PINEDA A, et al. The road to malignant cell transformation after particulate matter exposure:from oxidative stress to genotoxicity[J]. Int J Mol Sci, 2023, 24(2):1782. doi:10.3390/ijms24021782.
[14]	VOGELEY C, ROLFES K M, KRUTMANN J, et al. The aryl hydrocarbon receptor in the pathogenesis of environmentally-induced squamous cell carcinomas of the skin[J]. Front Oncol, 2022,12:841721. doi:10.3389/fonc.2022.841721.
[15]	MOKRZYNSKI K, KRZYSZTYNSKA-KULETA O, ZAWROTNIAK M, et al. Fine particulate matter-induced oxidative stress mediated by UVA-visible light leads to keratinocyte damage[J]. Int J Mol Sci, 2021, 22(19):10645. doi:10.3390/ijms221910645.
[16]	CASTANEDA A R, PINKERTON K E, BEIN K J, et al. Ambient particulate matter activates the aryl hydrocarbon receptor in dendritic cells and enhances Th17 polarization[J]. Toxicol Lett, 2018, 292:85-96. doi:10.1016/j.toxlet.2018.04.020.
[17]	PRASAD S N, NAGARKATTI M, NAGARKATTI P. From suppressor T cells to regulatory T cells:how the journey that began with the discovery of the toxic effects of TCDD led to better understanding of the role of AhR in immunoregulation[J]. Int J Mol Sci, 2020, 21(21):7849. doi:10.3390/ijms21217849.
[18]	KIM J, LEE J, LI X, et al. Single-cell transcriptomics suggest distinct upstream drivers of IL-17A/F in hidradenitis versus psoriasis[J]. J Allergy Clin Immunol, 2023, 152(3):656-666. doi:10.1016/j.jaci.2023.05.012.
[19]	DAVID E, CZARNOWICKI T. The pathogenetic role of Th17 immune response in atopic dermatitis[J]. Curr Opin Allergy Clin Immunol, 2023, 23(5):446-453. doi:10.1097/ACI.0000000000000926.
[20]	UBEROI A, BARTOW-MCKENNEY C, ZHENG Q, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor[J]. Cell Host Microbe, 2021, 29(8):1235-1248. doi:10.1016/j.chom.2021.05.011.
[21]	TSUJI G, YAMAMURA K, KAWAMURA K, et al. Novel therapeutic targets for the treatment of atopic dermatitis[J]. Biomedicines, 2023, 11(5):1303. doi:10.3390/biomedicines11051303.
[22]	黎敏, 龚坚, 吴伟伟, 等. Nrf2/HO-1通路在银屑病中作用的研究进展[J]. 天津医药, 2024, 52(5):552-556.
	LI M, GONG J, WU W W, et al. Research progress on the role of Nrf2/HO-1 pathway in psoriasis[J]. Tianjin Med J, 2024, 52(5):552-556. doi:10.11958/20231583.
[23]	JANG Y S, JEONG S, KIM A R, et al. Cannabidiol mediates epidermal terminal differentiation and redox homeostasis through aryl hydrocarbon receptor(AhR)-dependent signaling[J]. J Dermatol Sci, 2023, 109(2):61-70. doi:10.1016/j.jdermsci.2023.01.008.
[24]	UCHI H, YASUMATSU M, MORINO-KOGA S, et al. Inhibition of aryl hydrocarbon receptor signaling and induction of NRF2-mediated antioxidant activity by cinnamaldehyde in human keratinocytes[J]. J Dermatol Sci, 2017, 85(1):36-43. doi:10.1016/j.jdermsci.2016.10.003.
[25]	CHESSA M A, LA PLACA M, PATRIZI A, et al. Chloracne:a case series on cutaneous expression of CYP1A1 as diagnostic biomarker[J]. Clin Exp Dermatol, 2021, 46(5):896-900. doi:10.1111/ced.14617.
[26]	FURUE M, FUYUNO Y, MITOMA C, et al. Therapeutic agents with AHR inhibiting and NRF2 activating activity for managing chloracne[J]. Antioxidants (Basel), 2018, 7(7):90. doi:10.3390/antiox7070090.
[27]	PETIT R G, CANO A, ORTIZ A, et al. Psoriasis:from pathogenesis to pharmacological and nano-technological-basedtherapeutics[J]. Int J Mol Sci, 2021, 22(9):4983. doi:10.3390/ijms22094983.
[28]	MAN A M, ORASAN M S, HOTEIUC O A, et al. Inflammation and psoriasis:A comprehensive review[J]. Int J Mol Sci, 2023, 24(22):16095. doi:10.3390/ijms242216095.
[29]	DI MEGLIO P, DUARTE J H, AHLFORS H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions[J]. Immunity, 2014, 40(6):989-1001. doi:10.1016/j.immuni.2014.04.019.
[30]	BISSONNETTE R, STEIN G L, RUBENSTEIN D S, et al. Tapinarof in the treatment of psoriasis:A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent[J]. J Am Acad Dermatol, 2021, 84(4):1059-1067. doi:10.1177/12034754241239050.
[31]	LIN X, MENG X, LIN J. The role of aryl hydrocarbon receptor in the pathogenesis and treatment of psoriasis[J]. J Cutan Med Surg, 2024, 28(3):276-286. doi:10.1177/12034754241239050.
[32]	TIAN C, ZHANG G, XIA Z, et al. Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model[J]. Eur J Med Chem, 2022,231:114122. doi:10.1016/j.ejmech.2022.114122.
[33]	ZHANG G, XIA Z, TIAN C, et al. Discovery of 5-((1H-indazol-3-yl) methylene)-2-thioxoimidazolidin-4-one derivatives as a new class of AHR agonists with anti-psoriasis activity in a mouse model[J]. Bioorg Med Chem Lett, 2023,92:129383. doi:10.1016/j.bmcl.2023.129383.
[34]	SROKA-TOMASZEWSKA J, TRZECIAK M. Molecular mechanisms of atopic dermatitis pathogenesis[J]. Int J Mol Sci, 2021, 22(8):4130. doi:10.3390/ijms22084130.
[35]	FADADU R P, ABUABARA K, BALMES J R, et al. Air pollution and atopic dermatitis, from molecular mechanisms to population-level evidence:a review[J]. Int J Environ Res Public Health, 2023, 20(3):2526. doi:10.3390/ijerph20032526.
[36]	SMITS J, EDERVEEN T, RIKKEN G, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides[J]. J Invest Dermatol, 2020, 140(2):415-424. doi:10.1016/j.jid.2019.06.142.
[37]	PALLER A S, STEIN G L, SOUNG J, et al. Efficacy and patient-reported outcomes from a phase 2b,randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis[J]. J Am Acad Dermatol, 2021, 84(3):632-638. doi:10.1016/j.jaad.2020.05.135.
[38]	AHN Y M, SHIN S, JANG J H, et al. Bojungikgi-tang improves skin barrier function and immune response in atopic dermatitis mice fed a low aryl hydrocarbon receptor ligand diet[J]. Chin Med, 2023, 18(1):100. doi:10.1186/s13020-023-00806-9.
[39]	BANGASH Y, SALEEM A, AKHTAR M F, et al. Pterostilbene reduces the progression of atopic dermatitis via modulating inflammatory and oxidative stress biomarkers in mice[J]. Inflammopharmacology, 2023, 31(3):1289-1303. doi:10.1186/s13020-023-00806-9.
[40]	PENG G, TSUKAMOTO S, IKUTAMA R, et al. Human beta-defensin-3 attenuates atopic dermatitis-like inflammation through autophagy activation and the aryl hydrocarbon receptor signaling pathway[J]. J Clin Invest, 2022, 132(17):e156501. doi:10.1172/JCI156501.
[41]	PREDA-NAUMESCU A, AHMED H N, MAYO T T, et al. Hidradenitis suppurativa:pathogenesis,clinical presentation,epidemiology,and comorbid associations[J]. Int J Dermatol, 2021, 60(11):e449-e458. doi:10.1111/ijd.15579.
[42]	MORAN B, SWEENEY C M, HUGHES R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis,which is corrected by anti-TNF therapy[J]. J Invest Dermatol, 2017, 137(11):2389-2395. doi:10.1016/j.jid.2017.05.033.
[43]	DAJNOKI Z, SOMOGYI O, MEDGYESI B, et al. Primary alterations during the development of hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2022, 36(3):462-471. doi:10.1111/jdv.17779.
[44]	ROTHHAMMER V, QUINTANA F J. The aryl hydrocarbon receptor:an environmental sensor integrating immune responses in health and disease[J]. Nat Rev Immunol, 2019, 19(3):184-197. doi:10.1038/s41577-019-0125-8.
[45]	SZELEST M, WALCZAK K, PLECH T. A new insight into the potential role of tryptophan-derived AhR ligands in skin physiological and pathological processes[J]. Int J Mol Sci, 2021, 22(3):1104. doi:10.3390/ijms22031104.
[46]	HUNT A, QIAN V, OLDS H, et al. The current clinical trial landscape for hidradenitis suppurativa:A narrative review[J]. Dermatol Ther(Heidelb), 2023, 13(7):1391-1407. doi:10.1007/s13555-023-00935-x.